News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 97–108 of 243 stories

Lifebit Helps Launch Abu Dhabi Genomic Trusted Research Environment

Lifebit is one of the delivery partners, alongside M42 and Microsoft, for the Department of Health – Abu Dhabi's new Trusted Research Environment. Announced on 21 October, the protected research platform is designed to let approved researchers analyse genomic and health data under controlled access. It brings together approximately 950,000 genomes and extensive clinical records. Lifebit described the launch in a blog dated 29 October.

Rezera Files US IPO Registration to Support Phase 3 Ruvonoflast

Rezera, formerly NodThera, filed a Form S-1 registration statement with the US Securities and Exchange Commission on 21 October 2026 for a potential initial public offering. The company is developing NLRP3 inhibitors, including ruvonoflast, which it plans to advance into Phase 3 for peripheral artery disease. The filing does not establish that the share offering has priced, completed or begun trading.

Quell Therapeutics Advances QEL-005 to Second Dose Cohort in Phase 1/2 CHILL Trial

Quell Therapeutics has completed the first dose cohort of its Phase 1/2 CHILL trial of QEL-005, an engineered regulatory T cell therapy for rheumatoid arthritis and systemic sclerosis, with no dose-limiting toxicities or serious adverse events reported. The trial is moving to its second dose cohort, with initial clinical data expected in H1 2027.

Brainomix Highlights REVISE PPF Study Findings on CT Imaging

Brainomix has highlighted findings from the multicentre REVISE PPF observational study, which examined CT imaging data from 509 patients at three US centres. Researchers reported that e-Lung quantitative imaging measures identified radiological progression before recorded clinical diagnoses in several cohorts, while certain CT markers were associated with future disease progression and mortality. The retrospective study did not establish whether earlier identification improves patient outcomes.